Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...

Emory researchers are the first to show unprecedented control of SIV replication and decay of viral reservoirs by combining a ...

Researchers have shown unprecedented control of SIV replication and decay of viral reservoirs by combining a stringent model of infection with the interruption of antiretroviral therapy (ART). The ...

In a session at AIDS 2024, the International AIDS Conference, global leaders and community advocates gathered to discuss why ...

Radiant Biotherapeutics, whose labs are located in Toronto, aims to use the financing to pursue its signature technology, an ...

Current INSTI vs protease inhibitor or NNRTI use is linked to an increased risk for diabetes, which is slightly attenuated when adjusted for changes in BMI.

Along with breast cancer, cervical cancer is among the most feared cancer diagnoses for women around the world.

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to the first study to show such a benefit in these patients. After five ...

In a sneak peek of his panel discussion at this Thursday’s AI Deciphered summit, Merck’s digital privacy director ... and ViiV’s recent activation around HIV awareness in the South.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, including with Merck’s islatravir, experts said. Early lenacapavir ...